Skip to main content

Table 2 Circulating biomarkers and neutrophils stimulation profiles for patients with and without coronary allograph vasculopathy (CAV)

From: Decreased circulating and neutrophil mediated VEGF-A165 release in stable long-term cardiac transplant recipients

Parameters CAV ( n= 7) No CAV ( n= 11)
Biomarkers   
VEGF-A165 63.3 ± 27.8 48.4 ± 15.1
IL-8 6.20 ± 1.59 3.61 ± 0.74
IL-RA 331 ± 99 187 ± 30
Neutrophils/Factors   
VEGF release   
 PBS 10.5 ± 2.8 11.7 ± 1.9
 fMLP 47.1 ± 9.5 52.7 ± 9.3
 LPS 33.4 ± 5.5 46.7 ± 8.9
 TNF-α 51.7 ± 11.4 60.7 ± 10.6
IL-8 release   
 PBS 23.7 ± 5.3 14.7 ± 2.8
 fMLP 115 ± 19 161 ± 20
 LPS 1100 ± 115 1180 ± 67
 TNF-α 728 ± 81 898 ± 76
IL-1RA release   
 PBS 187 ± 43 229 ± 44
 fMLP 178 ± 43 248 ± 42
 LPS 253 ± 52 357 ± 54
 TNF-α 457 ± 66 515 ± 55
  1. CAV: Cardiac allograft vasculopathy; VEGF: Vascular endothelial growth factor; IL: Interleukin; RA: Receptor antagonist; PBS: Vehicule; fMLP: N-formyl-Met-Leu-Phe; LPS: Bacterial lipopolysaccharides; TNF: Tumor necrosis factor. Variables are expressed as mean ± SEM and percentages.